EGFR and small cell lung carcinoma: Mavelertinib and other related third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) block the proliferation of small-cell lung cancer by covalently binding the reactive acrylamide group to a cysteine residue in the ATP-binding domain of mutant EGFR tyrosine kinase in these cells (18).